VectorY Therapeutics
Amsterdam gene therapy company founded in 2020 developing vectorized antibody therapies, combining AAV-delivered intracellular antibodies with targeted protein degradation, for neurodegenerative and muscular diseases; lead program VTx-002 targets TDP-43 in ALS.
Headquarters
Amsterdam, Netherlands
Year Founded
2020
Founders
Carlo Incerti, Pavlina Konstantinova, Anthony Newcombe, Barbara Sanders; Sander van Deventer (CEO)
Country
Netherlands
Financial Information
Funding Stage
Series A
Recent Funding
$138M
Funding By
EQT Life Sciences, Forbion Growth Opportunities Fund, MRL Ventures Fund (Merck), Insight Partners, ALS Investment Fund, BioGeneration Ventures, Eli Lilly
Core Technology
Vectorized antibodies: AAV-delivered intracellular antibodies with targeted protein degradation
Product Type
Gene Therapy
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: No
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Not disclosed
Partnerships
Pharma Collaborations
Eli Lilly (seed investor); MRL Ventures Fund (Merck)
Academic / Hospital Tie-ups
Not disclosed
CRO/CDMO Partnerships
Not disclosed
Market & Differentiation
Combines AAV delivery with protein degradation to reach disease targets inside cells